The World Health Organization has announced the start of a clinical trial for two potential treatments against the Bundibugyo strain of Ebola in the Democratic Republic of Congo, where the outbreak has caused 438 deaths

The World Health Organization announced on Thursday, 2 July 2026, that a clinical trial of two potential treatments for the Bundibugyo species of Ebola had begun in the Democratic Republic of Congo, offering hope amid a severe outbreak in the northeastern provinces.

Also read: Nigeria strengthens Ebola preparedness, maintains zero cases

WHO Director-General Tedros Adhanom Ghebreyesus confirmed the enrolment of the first patient in the study evaluating the monoclonal antibody MBP134 and the antiviral drug remdesivir, both alone and in combination.

No approved vaccines or treatments currently exist for this rare strain of the virus. According to WHO figures, the outbreak has resulted in 1,406 confirmed cases, 438 confirmed deaths, and 208 recoveries.

The trial is being conducted by the DRC’s National Institute for Biomedical Research with support from international partners, including the WHO.

Patients enrolled will receive comprehensive supportive care and close medical follow-up.

Tedros emphasised the importance of the initiative: “Today, the clinical trial of two therapeutics began, with the enrolment of the first patient.”

He added that efforts are underway to ensure access to the drugs if they prove safe and effective.

This development marks a significant step in the response to the outbreak, which has devastated communities in the region.

The trial aims to deliver much-needed therapeutic options while maintaining rigorous standards of care for participants.

Also read: Tinubu approves N10bn Ebola preparedness fund

Health authorities continue to monitor the situation closely as the study progresses, with the potential for positive outcomes offering renewed optimism in the fight against this deadly virus.